Within the evolving landscape of novel and biomarker-driven therapies, there is an increasing need to identify disease-specific features including genetic alternations. Emerging evidence explores the potential to expand use of PARP inhibitors beyond the established role in germline BRCA mutations in other DNA damage repair pathway aberrations. In this interactive Clinical Case Challenge: test your knowledge in evaluating the role of genetic testing based on patient- and disease-specific characteristics in metastatic breast cancer identify evidence-based treatment options for patients using results from genetic testing compare your performance against your peers receive immediate feedback via expert-led, microlearning videos outlining key clinical evidence.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/cgagbrcabreast2024-gamified-approach-optimize-multidisciplinary
- Start Date: 2024-10-11 05:00:00
- End Date: 2024-10-11 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 37375.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 13875.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all